Liver fatty acid-binding protein (LFABP) is an abundant protein in hepatocytes that binds most of the long chain fatty acids present in the cytosol. It is suggested to be of importance for fatty acid uptake and utilization in the hepatocyte. In the present study, the effects of bovine GH (bGH) and other hormones on the expression of LFABP and its messenger RNA (mRNA) were studied in hypophysectomized rats and in vitro using primary cultures of rat hepatocytes. One injection of bGH increased LFABP mRNA levels about 5-fold after 6 h, but there was no effect of this treatment on LFABP levels. However, 7 days of bGH treatment increased both LFABP mRNA and LFABP protein levels 2-to 5-fold. Female rats had higher levels of LFABP than male rats. Hypophysectomy of female rats, but not that of male rats, decreased LFABP levels markedly. Treatment of hypophysectomized rats with bGH for 7 days as two daily injections or as a continuous infusion increased LFABP levels to a similar degree. This finding indicates that the sex difference in the expression of LFABP is not regulated by the sexually dimorphic secretory pattern of GH.
Neither insulin nor insulin-like growth factor I treatment of hypophysectomized rats for 6 -7 days had any effect on LFABP mRNA or LFABP levels. In vitro, bGH dose-dependently increased the expression of LFABP mRNA, but only in the presence of insulin. Insulin alone had a marked dose-dependent effect on LFABP mRNA levels and was of importance for maintaining the expression of LFABP mRNA during the culture. Incubation with bGH increased LFABP mRNA levels within 3 h. GH had no effect on LFABP mRNA levels in the presence of actinomycin D, indicating a transcriptional effect of GH. Incubation with glucagon in vitro decreased LFABP mRNA levels markedly, indicating that glucagon, in contrast to GH, has an effect opposite that of insulin on LFABP mRNA expression. It is concluded that GH is an important regulator of LFABP in vivo and in vitro. In contrast to the effect of GH on insulin-like growth factor I mRNA, the presence of insulin was a prerequisite for the effect of GH on LFABP mRNA expression in vitro. The results emphasize the role of GH in the regulation of hepatic fatty acid metabolism. (Endocrinology 139: 2699 -2709, 1998) G H HAS many effects on lipid and lipoprotein metabolism, including enhanced lipolysis and decreased lipogenesis in adipose tissue (1) (2) (3) , changes in serum lipoprotein concentrations, and hepatic lipid and lipoprotein metabolism (4 -7) . GH enhances hepatic mitochondrial ␤-oxidation of polyunsaturated fatty acids (8) partly via effects on fatty acid composition of mitochondrial phospholipids (9) . GH also decreases acetyl coenzyme A carboxylase activity (10) and fatty acid synthase messenger RNA (mRNA) (11) in the liver, indicating decreased fatty acid synthesis. GH therapy of hypophysectomized (Hx) rats increases triglyceride synthesis, fatty acid oxidation, and very low density lipoprotein assembly and secretion from hepatocytes (12) (13) (14) (15) . Incubation with GH in vitro increases the activity of phosphatidate phosphohydrolase in primary hepatocyte cultures (16) . Therefore, the enhanced triglyceride synthesis and very low density lipoprotein assembly in the liver after GH therapy in vivo must rely on an exogenous fatty acid supply.
Liver fatty acid-binding protein (LFABP) belongs to a family of abundant cytosolic small proteins (14 -15 kDa), which includes intestinal, ileal, heart, myelin, and adipocyte FABP as well as retinol-and retinoic acid-binding proteins. These FABPs, except for the last two proteins, are characterized by binding of long chain fatty acids and their coenzyme A esters (17) (18) (19) (20) (21) . In contrast to the other members of the FABP family, LFABP binds 2 mol fatty acid/mol protein (22) . The fatty acids bound to LFABP are preferentially long chain, unsaturated fatty acids. Moreover, LFABP has been shown to bind heme and a number of eicosanoids with high affinity and to bind a large number of other amphipathic ligands with lower affinity, such as bilirubin, bile salts, lysophosphatidylcholine, steroids, and their metabolites (17, 20, 21) . Several enzyme activities, especially those involved in microsomal fatty acid metabolism, were stimulated by LFABP (17) . LFABP may play a role as an intracellular acceptor of fatty acids, thereby enhancing fatty acid uptake and facilitating intracellular transport (17, (23) (24) (25) (26) (27) . Rat LFABP complementary DNA (cDNA) was cloned by Gordon and co-workers (28) , and the complete nucleotide sequence of the gene was found to contain four exons and three introns (17, 18) . LFABP mRNA levels in the liver are developmentally regulated, with a marked increase during the first 24 h after birth and during puberty in the rat (29, 30) , whereas LFABP protein levels increase more gradually (31, 32) . There is no or very small diurnal variation in LFABP levels (17, 32) . LFABP expression is induced by a high fat diet and peroxisome proliferators, such as bezafibrate and clofibric acid (17) . LFABP expression has also been shown to be influenced by hormones, but only in vivo. Female rats have higher levels than male rats (17, 26, 27) , and this difference was reversed by a combination of gonadectomy and administration of gonadal steroids (26) . Other studies on the hormonal regulation of LFABP have relied on measurements of the binding capacity of the cytosol fraction containing LFABP (33) (34) (35) . GH has been shown to increase the expression of LFABP mRNA in Hx male rats (30) , and the binding capacity of the cytosol fraction containing LFABP was increased in Hx rats given GH compared with that in Hx control rats (35) .
In the present study the effects of bovine GH (bGH), and other hormones on the expression of LFABP and its mRNA were studied in vivo in Hx rats. Cytosolic LFABP concentrations were measured with an antibody sandwich enzymelinked immunosorbent assay (ELISA). Primary cultures of hepatocytes were used to study the direct effect of bGH and other hormones on the expression of LFABP mRNA. Insulinlike growth factor I (IGF-I) mRNA levels were measured as an indication of GH responsiveness and the characteristics of GH regulation of LFABP mRNA. Rat hepatocytes were cultured on a basement membrane matrix (Matrigel) derived from extraction of the Engelbreth-Holm-Swarm sarcoma (36) . This system, which allows serum-free conditions, has been used to study in vitro effects of GH on cytochrome P-450 enzymes and IGF-I mRNA (37) . Moreover, LFABP mRNA and LFABP expressions have been shown to be induced by peroxisome proliferators when hepatocytes were cultured on Matrigel, but not when they were maintained on collagencoated plates (38) .
Materials and Methods

In vivo hormonal treatment
Sprague-Dawley rats (Mollegaard Breeding Center, Ejby, Denmark) were used. Hypophysectomy was performed at 50 days of age at Mollegaard Breeding Center. Intact normal rats were age matched. The rats were maintained under standardized conditions of temperature (24 -26 C) and humidity (50 -60%), with lights on between 0500 -1900 h. The rats had free access to standard laboratory chow (rat and mouse standard diet, B&K Universal, Sollentuna, Sweden) and water. Hormonal treatment started 7-10 days after hypophysectomy. If not otherwise stated, all Hx rats were given cortisol phosphate (400 g/kg⅐day; Solu-Cortef, Upjohn, Puurs, Belgium) and l-T 4 (10 g/kg⅐day; Nycomed, Oslo, Norway) diluted in saline as a daily sc injection at 0800 h (39) . Recombinant bGH was a gift from American Cyanamide Co. (Princeton, NJ). The hormone was diluted in 0.05 m phosphate buffer, pH 8.6, with 1.6% glycerol and 0.02% sodium azide. bGH (in most experiments 1 mg/ kg⅐day) was given either continuously by means of an Alzet osmotic minipump 2001 (Alza Corp., Palo Alto, CA) that was implanted sc on the back of the rat or as two daily sc injections at 12-h intervals (0800 and 2000 h) (39) . Recombinant human IGF-I was supplied by Genentech (South San Francisco, CA). IGF-I (1.25 mg/kg⅐ day) was diluted in saline and given as a continuous infusion by means of osmotic minipumps (Alzet 2001) (40) . Insulin (100 U/ml; Insulatard, Novo Nordisk, Copenhagen, Denmark) was diluted in saline and given as a daily sc injection at 1600 h. The insulin dose was gradually increased (41): days 1 and 2, 1.0 U/day; days 3 and 4, 2.0 U/day; and days 5-7, 3.5 U/day. The treatments continued for 6 -7 days before the rats were decapitated, trunk blood was collected, and the livers were removed. The livers were cut into pieces, immediately frozen in liquid nitrogen, and stored at Ϫ70 C until assays.
Hepatocyte cultures and hormones used in vitro
Hepatocytes were prepared by a nonrecirculating collagenase perfusion through vena porta of 200-to 300-g female Sprague-Dawley rats essentially as previously described (14) . The rats were anesthetized by a combination of xylazine (9 mg/kg; Rompun, Bayer, Lever-Kusen, Germany) and ketamine hydrochloride (77 mg/kg; Ketalar, ParkeDavis, Detroit, MI). The perfusion started with Hanks' Balanced Salt Solution without calcium and magnesium, pH 7.4 (Life Technologies, Paisley, Scotland) supplemented with 0.6 mm EGTA, 20 mm HEPES, and 10 mm sodium hydrogen carbonate. This solution was followed by perfusion with Williams' E medium with Glutamax (catalogue no. 32551, Life Technologies) supplemented with penicillin (50,000 IU/liter), streptomycin (50 mg/liter; Life Technologies), 0.28 mm sodium ascorbate (Sigma Chemical Co., St. Louis, MO), 0.1 m sodium selenite (Sigma Chemical Co.), and 300 -400 mg/liter collagenase A (Boehringer Mannheim, Mannheim, Germany), or 400 -500 mg/liter collagenase type IV (Sigma Chemical Co.). The first medium was given for 5-6 min at a flow rate of 40 -50 ml/min, and the second medium was given for 7-9 min at a flow rate of 40 ml/min. The perfusion media were kept at 37 C and infused continuously with 95% oxygen and 5% carbon dioxide. After the perfusion, the cells were filtered through a 250-m pore size mesh nylon filter followed by a 100-m pore size mesh nylon filter. The cells were washed by centrifugation at 50 ϫ g three times for 1 min each time at 4 C in Williams' E medium with Glutamax supplemented as described above (except for collagenase), but also supplemented with 3 g glucose/ liter and insulin (16 nm ϭ ϳ91 g/liter ϭ ϳ2600 mU/liter; Actrapid, Novo Nordisk; 28.6 U/mg). The cells were counted in a Burker chamber. The viability was about 90%, as determined by trypan blue exclusion at the start of the experiment and about 98 -100% at the end of the experiments. The cells were seeded at a density of approximately 170,000 cells/cm 2 in 10 ml medium on plastic dishes (56.7 cm 2 ; Nunclon, Nalge Nunc International, Copenhagen, Denmark) coated with 500 l Matrigel (Collaborative Research, Medical Products, Bedford, MA). The cells were plated during the first 16 -18 h in the same medium as that used for washing the cells. After 16 -18 h of culture, the cells were cultured in this medium but with different doses of insulin (Actrapid, Novo Nordisk), bGH (American Cyanamide Co.), or glucagon (Sigma Chemical Co.). Actinomycin D (5 g/ml; Sigma Chemical Co.) was dissolved in dimethylsulfoxide (DMSO). When actinomycin D was used, all culture dishes were cultured in medium containing 0.15% DMSO. The total culture time was 4 -5 days in all experiments. The medium was changed every day.
Production of antiserum
Rabbits (Russian, Mollegaard Breeding Center) were immunized with purified recombinant LFABP, which was a gift from Dr. D. Cistola, Washington University School of Medicine (St. Louis, MO). One hundred micrograms of LFABP were diluted in saline, mixed with equal volumes of Freund's complete or incomplete adjuvant, and injected im. Blood was collected from the ear vein (20 -30 ml every other week). The serum was shown to contain anti-LFABP antibodies by double immunodiffusion and Western blot. The IgG fraction was isolated by HiTrap protein G affinity columns according to the manufacturer (Pharmacia Biotech, Uppsala Sweden).
Cytosol preparation
Cytosol was prepared from rat liver. The tissue was homogenized in 2 ml homogenization buffer/g tissue according to the method of Ockner et al. (27) containing protease inhibitors (Complete Protease inhibitor cocktail tablets, Boehringer Mannheim). The homogenate was centrifuged for 20 min at 12,000 ϫ g. The supernatant was centrifuged for 1 h at 105,000 ϫ g. The total protein concentration of liver cytosol was determined by the method of Lowry et al. (42) . The cytosol was stored at Ϫ70 C until assay.
Western blot
Two micrograms of cytosol protein were added to each lane in a buffer containing 62.5 mm Tris-HCl (pH 6.8), 2.3% SDS, 10% glycerol, 0.001% bromophenol blue, and 5% ␤-mercaptoethanol. The samples were run overnight in 15% polyacrylamide gels containing SDS. The molecular mass standard See Blue (Novex, San Diego, CA) was used. The proteins were transferred to a polyvinyldifluoride membrane (Millipore) by semidry blotting (Multiphore II, Pharmacia). The membrane was then incubated with LFABP antiserum (1:200). Immunoreactive protein was visualized by chemiluminescence using an alkaline phosphatase-conjugated second antibody and AMPPD (disodium 3-(4-methoxyspiro(1,2-dioxetane-3,2'-tricyclo-[3.3.1.1 3, 7 ]decan)-4-yl)phenyl phosphate) as substrate (Tropix, Bedford, MA). The filters were exposed to ECL film (Amersham, Aylesbury, UK) at room temperature for 5-15 sec, and the films were subsequently developed.
ELISA
An antibody sandwich ELISA was developed to measure soluble LFABP in liver cytosol. The purified IgG fraction of the antirat LFABP antiserum was used. Biotinylation of the IgG fraction was performed using the Protein Biotinylation System (Life Technologies, Gaithersburg, MD). The ELISA was standardized using recombinant LFABP dissolved in rat heart cytosol. The protein concentration of recombinant LFABP was determined according to the method of Lowry et al. (42) . Rat heart cytosol was used as a carrier because it contains no or very low levels of LFABP. About 1-3 ng/l or 1 ng/g of a protein that cross-reacted with the antibody in heart cytosol were detected. The standard liver cytosol was obtained from a female rat (400 g) and contained 351 ng LFABP/l or 63 ng LFABP/g protein. The internal standard was obtained from a female rat (200 g) and contained 54 ng LFABP/g protein.
Microtiter plates (Costar, Cambridge, MA) were coated with the IgG fraction of the antiserum at a concentration of 10 g/ml in 50 l PBS with 0.05% sodium azide. The plates were incubated at room temperature overnight or at 4 C for at least 2 days before use. The plates were rinsed with distilled water and incubated with 200 l blocking buffer (PBS with 0.05% Tween-20 and 0.25% BSA, pH 7.2) for 30 min at room temperature and then rinsed with distilled water. The samples were added to the plate in a volume of 50 l diluted in blocking buffer and incubated for 2 h at room temperature. The plates were washed with distilled water, incubated with 200 l blocking buffer for 10 min, rinsed again before 50 l secondary antibody was added (biotinylated IgG, 400 ng/ml dissolved in PBS with 0.25% BSA, pH 7.2), and incubated for another 2 h at room temperature. The washing procedure was repeated, and streptavidin-alkaline phosphatase (Life Technologies) was added at a 1:8000 dilution in PBS with 0.25% BSA, pH 7.2, and incubated for 1.5 h. The plates were washed again and incubated with pNPP (Life Technologies) according to the manufacturer's directions. After 1 h, the plates were analyzed at 405 nm using a microtiter plate reader (model 450, Bio-Rad, Richmond, CA). The detection limit of the assay was 0.15 ng/l, or 7.5 ng absolute. The intraassay coefficient of variation (CV) was 5%. The interassay CV was 17% when the plates were assayed on different days, and the CV between plates assayed on the same day was 8%.
Probe synthesis
LFABP. The pJG418 plasmid containing a 515-bp insert in the pBR 322 (28) was a gift from Prof. J. Gordon, Washington University School of Medicine. The fragment obtained by cleavage of the 515-bp insert with PvuII and EcoRI (336 bp) was recloned into the pSP72 vector (Promega, Madison, WI). This new insert was used for the synthesis of a [
32 P]CTP cDNA probe (Megaprime, Amersham) for Northern blots. For solution hybridization assay, the pSP72 vector was linearized with PvuII, and a [ 35 S]UTP complementary RNA probe (antisense) was generated with T7 RNA polymerase (standard transcription protocol, Promega). The standard (sense) used in the solution hybridization assay was generated with SP6 RNA polymerase (Promega) using the same vector, linearized with EcoRI.
IGF-I.
A pSP64 vector (Promega) with a 153-bp genomic subclone of mouse IGF-I corresponding to exon 3 (by analogy to human IGF-I) was used (43) . The structure of this probe would allow detection of both forms of IGF-I mRNA. The hybridization signal in the solution hybridization assay was compared with that of a synthetic mRNA standard using an another construct in which the 153-bp fragment was inserted in the same vector in the opposite direction (44) .
Northern blot
Total RNA was prepared according to the method of Chomczynski and Sacchi 1987 (45) . Twenty micrograms of RNA were electrophoresed in an agarose (1%)-formaldehyde (0.66 m) gel. The RNA was transferred to a membrane (Hybond-N, Amersham) with a vacuum transfer system (LKB, Stockholm, Sweden) and baked at 80 C for 3 h. The membranes were prehybridized for 4 h at 42 C in a buffer containing 50% formamide, 25 mm HNa 2 PO 4 , 25 mm H 2 NaPO 4 , 5 ϫ SSC (standard citrate solution), 0.1% SDS, 1 mm EDTA, 0.05% BSA, 0.05% Ficoll, 0.05% polyvinylpyrrolidone, 200 g/ml calf liver RNA, and 200 g/ml salmon sperm DNA and hybridized for 12-14 h at 42 C in the prehybridization buffer, with the addition of a 32 P-labeled LFABP cDNA probe. Filters were washed once in 2 ϫ SSC-0.2% SDS at 42 C for 30 min and once 0.1 ϫ SSC-0.2% SDS at 42 C for 30 min. Autoradiography was performed at Ϫ70 C using Fuji medical x-ray film (Fuji Photo Film Co., Tokyo, Japan).
Solution hybridization
Total nucleic acids were prepared according to the method of Durnam and Palmiter (46) , and RNA was prepared according to the method of Chomczynski and Sacchi (45) from frozen liver and hepatocytes. The DNA content in the samples was analyzed as described by Labarca and Paigen (47) , and the RNA content was determined spectrophotometrically at 260 nm.
Aliquots of the prepared total nucleic acids or RNA samples were mixed with hybridization solution containing the 35 S-labeled LFABP or IGF-I complementary RNA probes, 0.6 m NaCl, 22 mm Tris-HCl (pH 7.5), 5 mm EDTA, 0.1% (wt/vol) SDS, 0.75 mm dithiothreitol, 7.5% (wt/vol) transfer RNA, and 25% (vol/vol) formamide in a total incubation volume of 40 l and hybridized at 70 C overnight (46) . The samples were then treated with 40 g ribonuclease A (RNase A) and 2 g RNase T1 in the presence of 100 g herring sperm DNA for 45 min at 37 C in a volume of 1 ml. Protected probe was precipitated with 100 l 6 m trichloroacetic acid (TCA). The precipitate was collected on glass-fiber filters (GF/C, Whatman International, Maidstone, UK) and counted in a scintillation counter. The signal was compared with a standard curve obtained by hybridization of in vitro transcribed LFABP mRNA or IGF-I mRNA. The intraassay CVs calculated from duplicates were 9% for the LFABP mRNA measurements and 14% for the IGF-I mRNA measurements. The results are expressed as attamoles of LFABP or IGF-I mRNA per g DNA or RNA.
Other methods
Serum insulin concentrations were determined by RIA (Phedabas, Pharmacia), and serum glucose concentrations were determined by the glucose-6-phosphate dehydrogenase method (Merck, Darmstadt, Germany) (40) .
Statistics
Values are expressed as the mean Ϯ sem. Comparisons between groups were made using one-or two-way ANOVA; comparisons between individual groups were made using the Student-Newman-Keuls multiple range test. The values were transformed to logarithms when appropriate.
Results
Effects of GH in vivo
Northern blot analysis revealed one band with the expected size (ϳ1 kb) of LFABP mRNA in the rat liver (Fig 1) . Northern blots of RNA preparations from adipose tissue, skeletal muscle, or heart did not reveal any transcripts, but RNA from the intestine contained a single band of similar size (data not shown). These results were expected from the known tissue distribution of LFABP mRNA (17, 20, 21, 29) . Figure 1 shows that liver from a Hx female rat treated for 7 days with T 4 and cortisol had less LFABP mRNA than liver from a normal female rat or livers from Hx rats treated with, in addition to T 4 and cortisol, bGH as two daily injections or as a continuous infusion.
The specificity of the antiserum raised against LFABP was tested by Western blotting. The detected band corresponded to the size marker with a molecular mass of 16 kDa (lysozyme; Fig. 2 ) and migrated as recombinant rat LFABP (data not shown). The expression of LFABP was lower in a Hx rat treated with T 4 and cortisol and higher in a Hx rat treated with bGH as two daily injections for 7 days (Fig. 2) .
To quantify the changes in LFABP mRNA and LFABP levels, a solution hybridization RNase protection assay and an antirat LFABP antibody sandwich ELISA were used. Hx female rats were treated with T 4 and cortisol for 3 days and thereafter given a single sc injection of 2 mg/kg bGH. The effects on LFABP mRNA, LFABP protein, and IGF-I mRNA levels were followed after the injection (Fig. 3, A-C) . Three hours after bGH injection, LFABP mRNA levels had increased significantly. IGF-I mRNA levels increased in a similar manner as LFABP mRNA, but IGF-I mRNA levels had decreased to basal levels 24 h after the injection, in contrast to LFABP mRNA levels (Fig. 3, A and C) . No obvious effect of the bGH injection on the expression of LFABP protein was observed in liver cytosol (Fig. 3B) . The changes in LFABP levels were similar when the amount of LFABP was calculated as milligrams of LFABP per g liver (data not shown).
Thus, it is not likely that an increased amount of certain major cytosolic proteins as a result of the bGH injection could have blunted an increase in LFABP levels.
Next, the effects of 7 days of hormonal treatment of Hx female rats were investigated. Hx rats given no hormonal treatment were compared with Hx rats given combined T 4 and cortisol treatment and, in addition, bGH as two daily injections (Table 1) . T 4 and cortisol treatment resulted in a , and IGF-I mRNA (C) in Hx female rats that had been pretreated for 3 days with T 4 (10 g/kg⅐day) and cortisol (400 g/kg⅐day). Control rats were not given bGH, and the other groups of rats were killed 1, 3, 6, or 24 h after the bGH injection. The concentrations of LFABP was determined with ELISA, and LFABP and IGF-I mRNA levels were determined with a solution hybridization assay as described in Materials and Methods. There were four or five rats in each group. Values are the mean Ϯ SEM. Values with different superscripts are significantly different from each other (P Ͻ 0.05, by one-way ANOVA followed by StudentNewman-Keuls test).
small, but significant, increase in LFABP levels, but had no effect on LFABP mRNA levels. The combination of T 4 , cortisol, and bGH increased LFABP levels nearly 3-fold and increased its mRNA 2-fold (Table 1) . To test the possibility that the effect of bGH on LFABP levels was influenced by treatment with T 4 and cortisol, bGH therapy alone was compared with combined T 4 , cortisol and bGH therapy in Hx female rats (Table 2) . GH treatment alone increased LFABP levels 1.5-fold and mRNA levels 2.7-fold, whereas combined T 4 , cortisol, and bGH treatment increased LFABP levels 2-fold and mRNA levels 2.5-fold (Table 2 ). In summary, these results show that GH has the capacity to increase LFABP levels without any additional pituitary-dependent hormones, but it cannot be excluded that T 4 and cortisol have some influence on LFABP protein levels.
Different doses of bGH were given as a continuous infusion to Hx female rats also treated with T 4 and cortisol (Fig.  4) . The lowest dose given (0.1 mg/kg⅐day) resulted in a 40% increase in LFABP concentrations. The highest doses (1 and 5 mg/kg⅐day) resulted in a normalization of the LFABP concentration (Fig. 4A) . As shown in Fig. 4B , an increased bGH dose resulted in an increased weight gain of the rats.
The next experiment was designed to compare the effects of Hx on cytosolic concentrations of LFABP in male and female rats as well as the effect of different modes of bGH administration (Fig. 5) . Several sexually dimorphic liver functions have been shown to be regulated by the sexually dimorphic secretory pattern of GH (4, 5, 7, 15, 48) . To investigate whether the secretory pattern of GH could influence the levels of LFABP, Hx female rats were given two daily injections of bGH, mimicking the male secretory pattern, or a continuous infusion of GH, mimicking the female secretory pattern. Female rats had 2.3-fold higher levels of LFABP than male rats (Fig. 5) . The effect of Hx was marked in female rats, but not in male rats. However, in other experiments (data not shown), a significant decrease in LFABP levels after Hx was observed in male rats. Two daily injections and a continuous infusion of bGH had similar effects on the expression of LFABP, resulting in 4.8-and 3.8-fold increases, respectively (Fig. 5) .
Effects of GH and insulin in vitro
To study the direct effects of GH on the expression of LFABP mRNA, primary hepatocyte cultures were used. In The effects of replacement therapy with T 4 (10 g/kg⅐day) and cortisol phosphate (C; 400 g/kg⅐day) and the additional treatment with bGH (1 mg/kg⅐day) of Hx female rats on the expression LFABP and its mRNA were investigated. The rats were Hx at 50 days of age, and hormonal treatment was started 7-10 days later. T 4 C was given as a daily sc injection; bGH was given as two daily sc injections. The hormonal treatment was given 7 days before death. The concentrations of LFABP and LFABP mRNA were determined as described in Materials and Methods. Values are the mean Ϯ SEM. There were seven rats in each group. In each column, values with different superscripts are significantly different from each other (P Ͻ 0.05, by one-way ANOVA followed by Student-Newman-Keuls test). The rats were Hx at 50 days of age, and hormonal treatment was started 7-10 days later. The rats were treated for 7 days with T 4 (10 g/kg⅐day) and cortisol phosphate (C; 400 g/kg⅐day). Bovine GH (1 mg/kg⅐day) was given as a continuous infusion by means of osmotic minipumps. LFABP concentrations in cytosol and LFABP mRNA levels were determined as described in Materials and Methods. Values are the mean Ϯ SEM. There were five rats in each group. In each column, values with different superscripts are significantly different from each other (P Ͻ 0.05, by one-way ANOVA followed by StudentNewman-Keuls test).
FIG. 4.
The effects of different doses of bGH on the concentration of LFABP in liver cytosol (A) and the daily weight gain (B) of hypophysectomized female rats. Age-matched female rats served as normal controls (N). All Hx rats were treated with T 4 (10 g/kg⅐day) and cortisol phosphate (C; 400 g/kg⅐day). bGH was given as a continuous infusion by means of osmotic minipumps in three doses (0.1, 1, and 5 mg/kg⅐day) for 7 days. The concentration of LFABP in liver cytosol was determined with ELISA as described in Materials and Methods. There were four or five rats in each group. Values are the mean Ϯ SEM. Bars with different superscripts are significantly different from each other (P Ͻ 0.05, by one-way ANOVA followed by Student-NewmanKeuls test).
the first experiment, the cells were treated with 16 nm insulin during the entire culture and were treated with bGH during the last 24 h. The highest dose of bGH was also given during the last 24 h of culture to cells that had not been treated with insulin the last 3 days of culture (Fig. 6A) . Incubation with 100 ng bGH/ml increased the LFABP mRNA level 2.3-fold. However, when no insulin was given during the last 3 days of culture, the level of LFABP mRNA was low despite bGH treatment, indicating an effect of insulin on LFABP mRNA levels (Fig. 6A) . In a separate experiment (Fig. 6B) , a different dose of bGH was given during the last 24 h to each cell culture dish. All culture dishes were incubated with 16 nm insulin during the entire culture period. The result of this experiment indicated that 100 -200 ng bGH/ml results in a maximal effect on LFABP mRNA expression. Thus, GH has a marked effect on LFABP mRNA levels in vitro, and this effect was dependent on the presence of insulin. In a control experiment, the level of LFABP mRNA in fresh isolated hepatocytes was compared with the level of LFABP mRNA after 16 h and 4 days of culture in the presence or absence of insulin (data not shown). The level of LFABP mRNA declined to about 60% of the level in fresh isolated cells after 16 h of culture in 16 nm insulin. In the presence and absence of 3 nm insulin, the LFABP mRNA levels were 34% and 14%, respectively, of the level in fresh isolated cells after 4 days of culture. Thus, insulin lessens the decline in LFABP mRNA gene expression during culture.
To further study the interaction between insulin and GH in the regulation of LFABP mRNA, hepatocytes were cultured during the first 16 -18 h with 16 nm insulin and thereafter were treated with different doses of insulin in the presence or absence of bGH (100 ng/ml) during the next 3 days of culture (Fig. 7, A and B) . bGH treatment had no effect on LFABP mRNA levels when the cells were not treated with insulin (Fig. 7A) , whereas bGH treatment resulted in 2.5-fold higher IGF-I mRNA levels in the absence of insulin (Fig. 7B) . When the data were analyzed with two-way ANOVA, it was found that both insulin and bGH treatment had a significant effect (P Ͻ 0.05) on LFABP mRNA and IGF-I mRNA levels. However, insulin had a marked effect on LFABP mRNA levels, but a small effect on IGF-I mRNA levels. GH, on the other hand, had a more marked effect on IGF-I mRNA than on LFABP mRNA levels. The combined action of 100 ng/ml bGH and 3 nm insulin resulted in a 10-fold increase in LFABP mRNA and a nearly 6-fold increase in IGF-I mRNA levels (Fig. 7, A and B) .
The time-dependent effects of GH and insulin on LFABP mRNA and IGF-I mRNA levels are shown in Fig. 8, A and B. One group of cultured cells was given 3 nm insulin during the last 3 days of culture. The fourth day of culture, bGH (100 ng/ml) was added to the medium for 1, 3, or 24 h. LFABP and IGF-I mRNA levels increased within 3 h of incubation (Fig.  8) . After 3 days of culture without insulin, other cultured cells were given 3 nm insulin for 1, 3, or 24 h. LFABP mRNA levels increased between 3 and 24 h of insulin treatment, whereas IGF-I mRNA levels were not affected by insulin in this experiment (Fig. 8) .
To determine whether the effect of bGH on LFABP mRNA levels was transcriptional, hepatocytes were cultured in the presence of bGH (100 ng/ml) and actinomycin D for 6 h (Fig. 9) . Incubation with actinomycin D alone did not affect LFABP mRNA levels, but the effect of bGH on LFABP mRNA levels was blunted in the presence of actinomycin D.
Effects of insulin and IGF-I in vivo
To determine whether insulin has an effect on LFABP mRNA and LFABP expression in vivo, insulin was given in FIG. 6 . Effects of different doses of bGH on the expression of LFABP mRNA in primary cultures of rat hepatocytes. Hepatocytes were isolated from a female rat and cultured as described in Materials and Methods. A shows an experiment in which three groups of cell culture dishes were cultured in the presence of 16 nM insulin (ϩ) during the entire culture. One group (Ϫ) was only treated with insulin during the first 16 -18 h (plating). Thereafter, insulin was withdrawn from the medium. bGH was given for the last 24 h in two different doses (20 and 100 ng/ml). B shows an experiment in which all cell culture dishes was treated with 16 nM insulin during the entire culture, and each culture dish was given a different dose of bGH during the last 24 h of culture (0, 2, 10, 20, 50, 100, 200, and 500 ng/ml). Total nucleic acids were isolated, and LFABP mRNA was measured with a solution hybridization assay as described in Materials and Methods. The values are the mean Ϯ SEM. In A, there were three dishes in each group. Bars with different superscripts are significantly different from each other (P Ͻ 0.05, by one-way ANOVA followed by Student-NewmanKeuls test).
FIG. 5.
The concentrations of LFABP in liver cytosol of normal male and female rats (N), Hx male and female rats given T 4 (10 g/kg⅐day) and cortisol (C; 400 g/kg⅐day), as well as Hx female rats given, in addition to T 4 and cortisol, bGH as two daily injections (GHϫ2) or as a continuous infusion by means of osmotic minipumps (GH c). Hormones were given for 7 days before death. The concentration of LFABP was determined by ELISA as described in Materials and Methods. There were six rats in each group. Values are the mean Ϯ SEM. Bars with different superscripts are significantly different from each other (P Ͻ 0.05, by one-way ANOVA followed by StudentNewman-Keuls test).
increasing doses for 7 days to Hx female rats (Table 3 ). Hx rats given T 4 and cortisol had lower serum insulin levels than normal rats, and bGH treatment increased serum insulin levels in the Hx rats. The insulin-treated Hx rats had similar or higher serum insulin levels than the Hx rats given bGH alone. The Hx rats given insulin alone had the lowest serum glucose levels. Insulin treatment and bGH treatment had opposite effects on serum glucose levels, and when both hormones were given together, intermediate serum glucose levels were observed. Insulin treatment had no effect on LFABP, LFABP mRNA, or IGF-I mRNA levels (Table 3) . However, bGH treatment (1 mg/kg⅐day) had the expected effects on IGF-I mRNA and LFABP expression (Table 3) . Although there are few or no IGF type 1 receptors in the liver (49), the effect of recombinant human IGF-I was tested in vivo, because IGF-I serum levels increase markedly as a result of GH therapy and, therefore, might affect other hormonal systems [such as an altered insulin secretion (50, 51) ] that could influence LFABP expression (Table 4) . However, there was no effect of 6 days of IGF-I treatment of Hx rats on either LFABP or its mRNA in the liver (Table 4) .
FIG. 7. Effects of different doses of insulin in the presence (open triangles)
or absence (filled squares) of bGH (100 ng/ml) on the expression of LFABP mRNA (A) and IGF-I mRNA (B) in primary cultures of hepatocytes. Hepatocytes were isolated from a female rat and cultured as described in Materials and Methods. All dishes were treated with 16 nM insulin during the first 16 -18 h. The cells were treated for 3 days with the indicated doses of insulin and bGH. Total nucleic acids were isolated, and LFABP mRNA and IGF-I mRNA were measured with a solution hybridization assay as described in Materials and Methods. The values are the mean Ϯ SEM. There were three dishes in each group. There was a significant effect of insulin and bGH treatment on LFABP and IGF-I mRNA levels (P Ͻ 0.05, by two-way ANOVA followed by Student-Newman-Keuls test).
FIG. 8.
Time-dependent effects of insulin and GH on the expression of LFABP mRNA (A) and IGF-I mRNA (B) in primary cultures of hepatocytes. Hepatocytes were isolated from a female rat and cultured as described in Materials and Methods. All dishes were treated with 16 nM insulin during the first 16 -18 h. The cells that were given bGH (open triangles; 100 ng/ml) for the indicated periods (1, 3, and 24 h) were treated with 3 nM insulin during the last 3-4 days of culture. Insulin (filled squares; 3 nM) was given for the indicated periods (1, 3, and 24 h). RNA was isolated, and LFABP mRNA and IGF-I mRNA were measured with a solution hybridization assay as described in Materials and Methods. Values are the mean Ϯ SEM. There were three or four dishes in each group. Values with different superscripts are significantly different from each other (P Ͻ 0.05, by one-way ANOVA followed by Student-Newman-Keuls test).
Effect of glucagon in vitro
One possible explanation for the lack of effect of insulin treatment in vivo on LFABP expression could be increased serum concentrations of insulin antagonistic hormones, which might have an effect on LFABP mRNA expression opposite that of insulin. One possible candidate for such an effect is glucagon, whose serum concentration is expected to be high when serum glucose levels decrease. Cultured cells were treated during the last 24 h of culture with 100 nm (348 ng/ml) glucagon. This treatment resulted in a marked decrease in LFABP mRNA levels (Fig. 10) .
Discussion
The lipolytic effect of GH in the rat results in an increased mobilization of fatty acids to the circulation (1, 2). Long chain fatty acids have been shown to function as hormones activating the peroxisome proliferator activated receptor (PPAR) (52, 53) . Activation of the PPAR results in enhanced LFABP mRNA and LFABP levels as well as induction of several mitochondrial and peroxisomal enzymes involved in fatty acid oxidation in the liver (38, 54) . Thus, GH could potentially increase LFABP expression in vivo via an increased flux of fatty acids to the liver. However, the present results show that GH has a direct effect on LFABP gene expression via its own receptor on hepatocytes. GH rapidly increased LFABP mRNA, but only in the presence of insulin. The lack of effect of GH on LFABP mRNA without insulin treatment was not due to a failure of the cells to respond to GH, as IGF-I mRNA levels increased 2.5-fold with GH alone. These results suggest that the LFABP gene, in contrast to the IGF-I gene, is dependent upon insulin for transcriptional regulation. Apart from the additive effects of insulin and GH on LFABP mRNA, the different time course for the induction of LFABP mRNA indicates different mechanisms of action of these hormones on LFABP mRNA expression.
The normalization of LFABP levels after GH therapy of Hx rats suggests that GH is a major regulator of LFABP expression. The increased concentration of LFABP in liver cytosol after GH therapy seems to at least in part be dependent on an increased amount of LFABP mRNA, as the mRNA and protein levels increased in parallel after a week of GH treatment. There was, however, no increase in the expression of LFABP 24 h after a single dose of bGH, although there was a marked effect on LFABP mRNA levels. Thus, an effect of GH on LFABP expression is dependent upon the presence of GH for a longer period of time. Induction of LFABP by peroxisome proliferators has also been shown to have a slow onset (17, 38) .
As GH treatment results in increased insulin secretion (55, 56) and increased serum concentrations of insulin, the in vivo effect of GH on LFABP levels may be the result of the additive effects of GH and insulin on LFABP mRNA expression. The lack of effect of insulin in vivo argues against this possibility. However, the rats given insulin had lower serum glucose concentrations, indicating increased serum concentrations of nonpituitary-dependent insulin antagonists such as glucagon. The inhibitory effect of glucagon in vitro indicates that the lack of effect of insulin in vivo could at least partly be explained by increased serum glucagon levels. Diabetic rats have been shown to have decreased cytosolic levels of LFABP, which were partly reversed by insulin treatment (33) . Thus, it is possible that insulin also has effects on LFABP expression in vivo, but only in insulin-deficient rats. The insulin concentrations in portal blood have been shown to be 0.34 nm (ϳ50 mU/liter) in the fasting rat (57) . This finding indicates that the portal levels of insulin are markedly higher than those in peripheral blood and that the doses used in the hepatocyte cultures were within or near physiological levels.
The GH doses used were in the physiological range, as indicated by the normal mean plasma levels of GH (50 -100 ng/ml) and the mean pulse heights of GH in plasma (150 -300 ng/ml) in the adult rat (58) . In the rat, GH secretion has been shown to decrease as a result of food deprivation for a period of 24 h or longer (59) . Together with low levels of insulin and high levels of glucagon in serum, decreased GH secretion would result in decreased hepatic LFABP levels. However, parallel decreases in the content of LFABP and total cytosol protein have been observed after prolonged fasting (17) , indicating that LFABP is not specifically decreased by fasting.
The continuous and irregular secretion of GH in the adult female rat and the regular episodic secretion of GH in the adult male rat have been mimicked in several studies by sc administration of GH as a continuous infusion and two daily injections of GH, respectively (4, 5, 15, 39, 48) . In contrast to many other sexually dimorphic hepatic functions in the rat, the higher levels of LFABP in female rats were not dependent upon the secretory pattern of GH. Therefore, the sex difference in LFABP levels could be dependent on direct effects of the gonadal steroids on the hepatocyte or, alternatively, occur via indirect effects on the A and B cells of the pancreatic islets. Thus, it has been shown that estradiol increases the Hepatocytes from a normal female rat were cultured as described in Materials and Methods. All culture dishes were incubated with 3 nM insulin during the last 3 days of culture. Actinomycin D (5 g/ml) and bGH (100 ng/ml) were given for 6 h. All culture dishes were cultured in the presence of 0.15% DMSO during the last 6 h of culture. LFABP mRNA was measured with a solution hybridization assay as described in Materials and Methods. Values are the mean Ϯ SEM. There were three or four dishes in each group. Values with different superscripts are significantly different from each other (P Ͻ 0.05, by one-way ANOVA followed by Student-Newman-Keuls test).
relative insulin to glucagon molar ratio in the portal vein (57) . In line with the present results, this effect of estradiol would result in increased expression of LFABP mRNA in the liver.
The effect of GH on LFABP mRNA was compared with the effect on IGF-I mRNA, as GH is a known regulator of IGF-I mRNA in hepatocytes in vivo and in vitro (37, 43) . Insulin has also been shown to play a role in the regulation of IGF-I mRNA in vitro (37, 60) . In line with these studies, we observed a 2-fold potentiation of the GH-induced expression of IGF-I mRNA by insulin treatment. We observed small or no effects of insulin alone on the expression of IGF-I mRNA. The half-maximal effective dose of insulin observed by others (0.47 nm) (60) is in line with our results. The lack of effect of insulin therapy of Hx rats on IGF-I mRNA could be due to a relatively small effect of insulin on IGF-I gene expression and also to the fact that the rats were not insulin deficient.
The mechanism of induction of LFABP mRNA by GH is at least partly an increased transcription rate of the gene, as indicated by the lack of effect of GH in the presence of actinomycin D. IGF-I mRNA levels increase after GH therapy as a result of an increased transcription rate (43, 61) . The induction of IGF-I mRNA in vivo by a single dose of GH was shown to be transient, in contrast to the induction of LFABP mRNA. This finding may reflect a transient increase in serum GH levels, resulting in an increased transcription followed by degradation of IGF-I mRNA. The maintained LFABP mRNA levels in the same experiment indicates slower turnover of LFABP mRNA than of IGF-I mRNA. The slow induction of LFABP mRNA by insulin treatment will be of interest to study further. It may be that the increase in LFABP mRNA levels caused by insulin treatment reflects an increased stability of the transcript, and the permissive action of insulin on the GH induction of LFABP mRNA may be due to this effect of insulin.
Cytosolic LFABP levels have previously been measured by immunological methods using radial immunodiffusion (17, 27) and direct noncompetitive ELISA (32) . Similar amounts of LFABP in the liver of mature (ϳ60 days of age) male and female rats were observed in this study and in other studies using immunological methods (17, 27) . We used the Lowry procedure for determination of protein concentrations. Overestimation of LFABP levels has been reported to occur when purified LFABP is measured according to the Lowry procedure (32) . Thus, it cannot be excluded that we overestimated the amount of LFABP, especially if there was no overestimation of the total protein concentration in cytosol. Nonimmunological measurements of the amount of LFABP in liver cytosol have relied on the property of LFABP to bind various ligands. There are sometimes discrepancies between the nonimmunological and immunological measurements of the amount LFABP (32) . Nonimmunological methods have several disadvantages compared with the immunological meth- Female rats were Hx at 50 days of age. Age-matched female rats served as normal controls (N). After 7-10 days of observation, the rats were hormonally treated for 7 days. All Hx rats were given T 4 (10 g/kg⅐day) and cortisol phosphate (C; 400 g/kg⅐day) as a daily sc injection. Bovine GH (1 mg/kg⅐day) was given as two daily sc injections. Insulin (Insulatard) was given as a daily sc injection at 1600 h. The dose was gradually increased: days 1 and 2, 1.0 U/day; days 3 and 4, 2.0 U/day; and days 5-7, 3.5 U/day. The analyses were performed as described in Materials and Methods. There were five or six rats in each group. Values are the mean Ϯ SEM. Values with different superscripts are significantly different from each other (P Ͻ 0.05, by one-way ANOVA followed by Student-Newman-Keuls test). Hypophysectomy was performed when the rats were 50 days old. Hormonal treatment started 7-10 days later. All Hx rats were treated with T 4 (10 g/kg⅐day) and cortisol phosphate (C; 400 g/kg⅐day). IGF-I (1.25 mg/kg⅐day) was given sc by means of osmotic minipumps. After 6 days of hormonal treatment, the rats were killed, and the livers were excised. LFABP concentrations in cytosol and LFABP mRNA levels were determined as described in Materials and Methods. There were seven rats in each group. Values are the mean Ϯ SEM. Values with different superscripts are significantly different from each other (P Ͻ 0.05, by one-way ANOVA followed by StudentNewman-Keuls test).
FIG. 10. The effect of glucagon (100 nM) on the expression of LFABP mRNA in primary cultures of hepatocytes. Hepatocytes were isolated from a female rat and cultured as described in Materials and Methods. All dishes were treated with 16 nM insulin the first 16 -18 h. Thereafter, hormones were withdrawn for 2 days, and glucagon was given during the last 24 h of culture. RNA was isolated, and LFABP mRNA was determined with a solution hybridization assay as described in Materials and Methods. Values are the mean Ϯ SEM. There were four dishes in each group. Values with different superscripts are significantly different from each other (P Ͻ 0.05, by Student's t test).
ods, such as competition with endogenous ligands, nonspecific binding, binding stoichiometry of LFABP, and the possibility that the ligands bind to other proteins in the low mol wt protein fraction. However, the results obtained using a ligand binding assay to determine the amount of LFABP in liver cytosol after hypophysectomy and GH therapy were similar to the results obtained in this study (35) .
In summary, GH was shown to have a marked effect on LFABP regulation. Small or no effects of thyroid hormones, glucocorticoids, insulin, and IGF-I could be detected in vivo using Hx rats. In contrast to other sexually dimorphic hepatic proteins, LFABP was not differently regulated by the maleand female-specific secretory patterns of GH. The induction of LFABP by GH in vivo was accompanied by an increase in LFABP mRNA, indicating a pretranslational regulation of LFABP expression by GH. However, a posttranslational regulation cannot be excluded. The in vitro studies indicate a direct hormonal regulation of LFABP mRNA expression involving physiological concentrations of insulin and GH. Thus, in addition to the known in vitro activation of LFABP via the PPAR␣ receptor and its presumed ligands, long chain fatty acids (19, 38, (52) (53) (54) , insulin, and GH receptors are involved in the regulation of LFABP gene expression. We cannot exclude the possibility that fatty acids mobilized as a result of GH treatment activate the PPAR␣ receptor and augment the direct effect of GH on the hepatocyte on LFABP expression. The role of LFABP in the diverse effects of GH on hepatic lipid and lipoprotein metabolism (1, 2, 4 -16) is still unclear. It could be speculated that GH increases intracellular trafficking of fatty acids in hepatocytes at least partly via a direct effect on the expression of LFABP.
